Brain HealthGLP-1 Drugs May Treat Addiction and Depression Simultaneously
GLP-1 receptor agonists — drugs like semaglutide originally designed for diabetes and obesity — appear to influence brain circuits involved in addiction and mood disorders. This review examines preclinical and early clinical evidence showing these drugs may reduce drug-seeking behavior, alcohol craving, and depressive symptoms by acting on dopamine, glutamate, and GABA pathways in the brain's reward centers. People with both substance use disorders and depression or anxiety — called dual disorders — currently have very limited treatment options. GLP-1 drugs could potentially address both conditions at once. However, clinical evidence remains preliminary, trials are small, and well-powered randomized studies specifically targeting dual-disorder populations have not yet been conducted.
